Targeted radiopharmaceuticals FOR PRECISION ONCOLOGY
Our focus is on collaborating with biopharmaceutical companies to design new targeted radiopharmaceuticals.
DEVELOPMENT
Co-development through partnerships in R&D projects.
VALIDATION
Test the radiopharmaceutical in animals and humans.
PROTECTION
Ensure assets exclusivity by combining different IPR tools.
MONETIZATION
Assets monetization through IP licensing and sublicensing.
YSOTOPE uses the molecule (MI) developed by the biopharmaceutical company to design new radiopharmaceuticals for precision diagnostics and targeted radiotherapy.
YSOTOPE provides:
- Co-diagnostic radiotracers for precision imaging and patient stratification, combining the molecule with diagnostic radioisotopes.
- Radiopharmaceuticals for targeted radiotherapy, combining the molecule with therapeutic radioisotopes.
TEAM
Carlos LANGEBER
CEO
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Natalia BENITO
COO
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Raúl HERANCE
CTO
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Our support
MQR Bikes
Commercial photography
MQR Bikes
Commercial photography
Poetry moves
Arty projects